Drugs / doxribtimine
doxribtimine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Kygevvi | — | 2026-03-26 | europa.eu ↗ |
| Approved | US (FDA) | KYGEVVI | — | 2025-11-03 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06754098 | Jan 2025 → Jan 2027 expected | inborn mitochondrial myopathy, mitochondrial DNA depletion syndrome, myopathic form | Cristina Domínguez González | Recruiting | No outcome recorded |
| Phase 2 | NCT03845712 | Jul 2019 → Jul 2026 overdue | mitochondrial DNA depletion syndrome, myopathic form | UCB BIOSCIENCES, Inc. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06590493 | — | mitochondrial DNA depletion syndrome, myopathic form | UCB BIOSCIENCES, Inc. | Available | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-17 | UCB Pharma | UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d) ucb.com ↗ |
| 2026-03-31 | UCB Pharma | European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d) ucb.com ↗ |
| 2026-01-30 | UCB Pharma | KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d) ucb.com ↗ |
| 2025-11-03 | UCB Pharma | U.S. FDA approves KYGEVVI[™] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) ucb.com ↗ |
| 2025-10-13 | UCB Pharma | Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) ucb.com ↗ |
| 2025-03-19 | UCB Pharma | New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference ucb.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxribtimine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06754098 ↗ |
| Known as | 2'-deoxythymidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Deoxyribothymidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Doxribtimine component of mt-1621 2'-deoxythymidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | MT1621 (dT) | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | NSC-21548 | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Thymidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Thymidinedeoxyriboside | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Thymine-2-desoxyriboside | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Zidovudine related compound d | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Known as | Zidovudine related compound d rs | ChEMBL registry synonym — accepted as the source's own label CHEMBL52609 ↗ |
| Modality | Small molecule | “Combination Pyrimidine Nucleosides” NCT03845712 ↗ |
| Route | Oral | “Doxecitine and doxribtimine is administered orally” NCT03845712 ↗ |